After Ambala, alert in K'shetra for white dwarf virus in paddy crops
The agriculture department in Ambala disclosed about the spread of Southern Rice Black Streaked Dwarf Virus in nearly 400 acres of paddy crop.
The total area under paddy crop in Ambala is 91,000 acres.
Deputy director agriculture (DDA) Ambala Jasvinder Saini said that there have been signs of the virus majorly in the villages of Mullana, Saha and Naraingarh areas of the district.
'The major impact has been on non-basmati varieties early sown using non-DSR methods. The virus poses a serious threat to crop productivity and growth. If the virus is not detected timely, it may affect the yield by nearly 80%. The department has issued an advisory to farmers to uproot and bury the affected plants and ensure regular monitoring,' he said.
On Tuesday, agriculture experts visited the fields and collected samples for testing.
Meanwhile, an alert was sounded in bordering Kurukshetra district in view of the suspected spread.
Following the reports, the experts and agricultural scientists have visited the fields.
The farmers are advised to keep a close watch, approach the department if the signs of virus and white-backed plant hoppers are witnessed and use the recommended insecticides.
The farmers are also advised to use the recommended insecticides to control the spread.
DDA Kurukshetra Karam Chand said that the alert was issued after a couple of findings were made by our field staff.
'There is no panic-like situation yet. I've instructed the staff to conduct field surveys and asked them to report well in time for action. Farmers have also been advised to remain alert and if such a problem arises, then adopt the treatment with the advice of agricultural experts, so that the growth of the crop is not affected,' he said.
The DDA said that its main identification is excessive dwarfing of plants in patches or pieces at some places in the fields; the colour of the leaves also turns dark green.
He further advised that to control the spread when 5-10 adult aphids are seen per plant, mix 80 grams (16% AI) of dinotifuron 20%, SG (osheen 20% SG) or token 20% SG in 200 liters of water and spray per acre. He said that for controlling white backed aphids, when 5-10 hoppers are seen per plant, mix 120 grams of pymetrozine 50%, WG (chase 50% WG) or 80 grams of dinotifuron 20% SG (token 20% SG) in a similar manner.
Meanwhile, crop scientists inspected the fields of farmers in Khedi Ramnagar, Amin and Fatuhpur villages of Kurukshetra district.
During this, they found that the problem of dwarfism is visible in some paddy plants in the fields.
Scientists said the farmers that due to this problem, such paddy plants remain smaller than healthy plants and later their growth stops.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
NRIs turning to India for high-quality quality affordable healthcare, customers up 150% YoY in FY25: Report
New Delhi [India], July 28 (ANI): Non-Resident Indians (NRIs) are increasingly choosing India as their destination for high-quality and affordable healthcare, according to the data released by Policybazaar. The data showed a significant 150 per cent growth in the share of NRI customers in FY 2024-25 compared to FY 2023-24, highlighting India's growing appeal in the global medical tourism space. It stated, "India is fast emerging as one of the world's most sought-after medical tourism hubs. The growth is quite visible with more NRIs turning to India to access high-quality healthcare. Our data indicates a 150 per cent overall growth in the share of NRI customers in FY 25". One of the key reasons behind this mentioned in the data report is the surge is the massive cost advantage India offers for medical treatments when compared to countries like the United States and the United Kingdom. For instance, heart bypass surgery in India costs between USD 5,000 and USD 8,000, while the same procedure in the U.S. can cost between USD 70,000 and USD 150,000. Similarly, a knee replacement surgery costs only USD 4,000 to USD 6,000 in India, compared to USD 30,000 to USD 50,000 in the U.S. A liver transplant in India is priced between USD 25,000 and USD 35,000, whereas it costs USD 300,000 to USD 500,000 in the U.S. NRIs opting for elective procedures in India typically have average claim amounts ranging from USD 2,000 to USD 15,000. For more complex surgeries, the claims may rise to USD 20,000 to USD 40,000, still representing considerable savings when compared to international healthcare costs. The affordability factor also extends to health insurance premiums. In India, the average annual health insurance premium per person ranges from USD 120 to USD 300. In contrast, the same coverage in the U.S. can exceed USD 8,000 annually, while in GCC countries, it ranges from USD 4,000 to USD 5,000. This significant difference has led to a visible increase in online searches by NRIs exploring health insurance options in India for themselves and their families. The data further reveals a 125 per cent surge in the share of women NRI customers and a 148 per cent increase in the number of NRI customers under the age of 35. This showed that younger NRIs and women are increasingly considering Indian healthcare as a preferred choice. When it comes to preferred locations for treatment, South Indian cities continue to dominate the list across all tiers. Cities like Mumbai, Kolkata, Pune, and Thane are also gaining popularity among NRI patients. With a combination of quality care, advanced medical infrastructure, and substantial cost benefits, India is rapidly emerging as a leading hub for NRI medical needs. (ANI)
Hindustan Times
6 hours ago
- Hindustan Times
2 months on, sewage chokes Rajendra Park; locals claim civic apathy
For over two months, residents of Rajendra Park in Ward 34 have been battling a severe sanitation crisis, with sewage water flooding streets, blocking roads, and threatening public health, residents said. The issue, which began as a drainage problem on July 8, has since escalated into what locals described as a full-blown hazard—marked by stagnant wastewater, foul stench, and rising cases of illness. An inundated street in Rajendra Park, Sector 105. (HT Photo) Despite filing multiple complaints on the Municipal Corporation of Gurugram (MCG) portal, attending grievance camps, and submitting a detailed letter to the deputy commissioner on July 24, the problem remains unresolved, locals claimed. 'We have done everything—complaints, meetings, even documentation with dates—but no one is acting,' said a resident. A widely shared video from July 23 starkly captured the extent of the problem, showing dirty sewage water encircling the Lord Shiva Temple at Gol Chakkar. 'I used to go to the temple twice a day,' said Rani, 68, a long-time devotee. 'Now I can't even step out. I nearly fell last week outside my house,' she added. Local businesses are also suffering, residents said. 'My customers avoid this area now. I am unable to pay my rent. This shop is our only source of survival,' said Shyam Pal Shekhawat, 40, who runs a grocery store nearby. The elderly are among the worst affected. Mange Ram Yadav, a 75-year-old retired army veteran and environmentalist, said even his medicines no longer get delivered. 'The delivery boys refuse to come here,' he said, adding, 'This place I once proudly kept green is now unrecognisable.' An inundated stretch in the area. (HT Photo) The crisis has also raised serious safety concerns. On July 19, a sewer line dug for cleaning was reportedly left open, creating a hazard for pedestrians. 'It's a death trap,' said a local parent. 'Children could fall in any time.' Mobility and housing have also taken a hit. Pramod Sharma, a resident and shop owner, said, 'I can't even reach Gurugram Railway Station without stepping through filth. I haven't had a tenant in months due to the mess.' As the sewage continues to overflow, residents are reporting a surge in health complaints, including skin infections, persistent coughing, and foul odours seeping into homes. Several residents also said Ramzan observances were disrupted due to the unhygienic surroundings. In response to the situation, MCG Commissioner Pradeep Dahiya said a team would inspect the site on Monday to initiate corrective action. However, residents remained sceptical. 'The hope is that this time, action will follow the promises,' one of them said. 'Residents have been grappling with this issue for over 12 years, and it's not something that can be fixed overnight,' said Surekha Chauhan, councillor of Ward 34. 'The sewer lines haven't been cleaned in all these years, which is what led to the current situation. We have already floated a tender, and once the monsoon subsides, desilting and cleaning work will begin in full swing. The rains have caused some delays, but the process is underway—and gradual cleaning has already started. It will take some time, but we are fully committed to resolving the issue.'
Economic Times
12 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
